ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2905

Rilonacept in Recurrent Pericarditis: Efficacy and Safety Data from an Ongoing Phase 2 Pilot Clinical Trial

Allan Klein 1, David Lin 2, Paul Cremer 1, Saifullah Nasir 3, Sharon Crugnale 4, Larisa Collins 4, Fang Fang 4, Anna Beutler 4 and John F Paolini4, 1Cleveland Clinic, Cleveland, OH, 2Minneapolis Heart Institute - Minneapolis, Minneapolis, MN, 3Stat! Cardiologist, Chicago, IL, 4Kiniksa Pharmaceuticals Corp, lexington, MA

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: cardiovascular disease and inflammation, IL-1, inflammatory cytokines, Traps

  • Tweet
  • Email
  • Print
Session Information

Date: Wednesday, November 13, 2019

Session Title: 6W020: Miscellaneous Rheumatic & Inflammatory Disease III: Novel Therapies (2900–2905)

Session Type: ACR Abstract Session

Session Time: 11:00AM-12:30PM

Background/Purpose: Recurrent pericarditis (RP) is characterized by the recurrence of pericarditis signs and symptoms after a symptom-free period of ≥4 to 6 weeks and affects 20-30 % of acute pericarditis patients. IL-1α/β, mediators of the inflammatory process, predominate in recurrent pericarditis (RP).

Methods: Participants with symptomatic or corticosteroid (CS)-dependent idiopathic or post-pericardiotomy RP receive subcutaneous rilonacept: 320 mg load, 160 mg weekly plus NSAIDs, colchicine and/or CS for the 6-week treatment period (TP). During optional 18-week treatment extension (EP), weekly rilonacept treatment continued while background therapy may be weaned. Primary endpoints are change in patient-reported pericardial pain (NRS, 11-point scale) and CRP in Parts 1, 2, 4 (symptomatic) and disease activity after CS taper in Parts 3, 5 (CS-dependent).

Results: As of Jan 23, 2019: 25 idiopathic RP patients enrolled (mean 3 episodes). Part 1: mean pericardial pain (NRS score) decreased from 4.6 (baseline) to 0.8 and CRP decreased from 4.9 mg/dL (baseline) to 0.30 mg/dL at 6 weeks (Figure 1); median 9 days to CRP normalization and objective pericarditis features (pericardial effusion, ECG changes, pericardial rub) resolved (Table 1). Parts 2, 4: reductions in NRS (Pain) and CRP were observed during the TP. Parts 3 and 5: pain and CRP remained low on rilonacept therapy during the TP and the effects of rilonacept on NRS and CRP were maintained during CS-taper/discontinuation in EP among those that completed 24 weeks of therapy. Among the 11/25 who completed the EP; 4/4 on baseline CS successfully tapered off CS; 3/3 discontinued NSAIDs and 2/8 discontinued colchicine. AEs occurred in 23 participants (92%; 12/23 drug-related), most commonly mild transient injection site reactions (no discontinuations).

Conclusion: Data from this ongoing Phase 2 study suggest weekly rilonacept administration results in improvement in patient-reported pericardial pain and objective measures in patients with idiopathic RP. Improvements were durable, supporting CS tapering. AEs were consistent with the known safety profile of rilonacept. These data supported the design of a Phase 3, placebo-controlled, global RHAPSODY trial (NCT03737110).


Figure 1 KINIKSA ABSTRACT Ph2 Results

Figure 1. Rapid and Sustained Reductions in NRS Scores -Pain- and CRP Levels After the First Dose -Part 1-

Table 1. Treatment with Rilonacept Resulted in Resolution of Pericardial Rub, ECG Changes, and Pericardial Effusion on Echocardiography


Disclosure: A. Klein, Kiniksa Pharmaceuticals, 2, Sobi, 5, Elsevier, 7; D. Lin, None; P. Cremer, Sobi, 5; S. Nasir, None; S. Crugnale, Kiniksa Pharmaceuticals, 3; L. Collins, Kiniksa Pharmaceuticals, 3; F. Fang, Kiniksa Pharmaceuticals, 3; A. Beutler, Kiniksa Pharmaceuticals, 3; J. Paolini, Kiniksa Pharmaceuticals, 3.

To cite this abstract in AMA style:

Klein A, Lin D, Cremer P, Nasir S, Crugnale S, Collins L, Fang F, Beutler A, Paolini J. Rilonacept in Recurrent Pericarditis: Efficacy and Safety Data from an Ongoing Phase 2 Pilot Clinical Trial [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/rilonacept-in-recurrent-pericarditis-efficacy-and-safety-data-from-an-ongoing-phase-2-pilot-clinical-trial/. Accessed May 16, 2022.
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rilonacept-in-recurrent-pericarditis-efficacy-and-safety-data-from-an-ongoing-phase-2-pilot-clinical-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.